Emergent BioSolutions (EBS) Intangibles (2013 - 2026)

Emergent BioSolutions' Intangibles history runs 14 years deep, the most recent figure standing at $470.4 million for Q1 2026.

• On a quarterly basis, Intangibles fell 3.05% year-over-year to $470.4 million in Q1 2026; TTM through Mar 2026 was $470.4 million, a 3.05% decrease from a year earlier, with the FY2025 full-year figure at $436.5 million, down 12.96% from the prior year.
• Intangibles grew to $470.4 million in Q1 2026 per EBS's latest filing, from $436.5 million in the prior quarter.
• Across five years, Intangibles topped out at $728.8 million in Q4 2022 and bottomed at $436.5 million in Q4 2025.
• The 5-year median for Intangibles is $550.4 million (2024), against an average of $552.3 million.
• Across the five-year window, Intangibles grew 20.54% in 2022 and retreated 22.26% in 2023, its largest moves.
• Year by year, Intangibles stood at $728.8 million in 2022, then retreated by 22.26% to $566.6 million in 2023, then declined by 11.49% to $501.5 million in 2024, then fell by 12.96% to $436.5 million in 2025, then increased by 7.77% to $470.4 million in 2026.
• Per Business Quant, the three latest EBS Intangibles figures stand at $470.4 million (Q1 2026), $436.5 million (Q4 2025), and $452.7 million (Q3 2025).